ITIL-306-201: A Multicenter, First-in-Human Phase 1a/1b Study of ITIL-306, an Engineered Autologous TIL Cell Therapy Product, in Adults With Advanced Solid Tumors Post date November 12, 2022 ← Clinical feasibility and treatment outcomes with nonselected autologous tumor-infiltrating lymphocyte therapy in patients with advanced cutaneous melanoma → Anti-folate Receptor Alpha (FRα) CoStimulatory Antigen Receptor (CoStAR™) Improves T-cell Function Across Physiologically Relevant Ranges of FRα Expression and T-cell Receptor Affinities
Instil Bio